Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 62

1.

"Lazy" nigrostriatal synapses in the heterozygous PINK1 mouse model of familial Parkinson's disease.

Calabresi P, Ghiglieri V.

Mov Disord. 2014 Jan;29(1):11-4. doi: 10.1002/mds.25759. Epub 2013 Dec 19. No abstract available.

PMID:
24357533
2.

Impact of the lesion procedure on the profiles of motor impairment and molecular responsiveness to L-DOPA in the 6-hydroxydopamine mouse model of Parkinson's disease.

Francardo V, Recchia A, Popovic N, Andersson D, Nissbrandt H, Cenci MA.

Neurobiol Dis. 2011 Jun;42(3):327-40. doi: 10.1016/j.nbd.2011.01.024. Epub 2011 Feb 19.

PMID:
21310234
3.

Partial damage to nigrostriatal bundle: compensatory changes and the action of L-dopa.

Zigmond MJ, Abercrombie ED, Stricker EM.

J Neural Transm Suppl. 1990;29:217-32. Review.

PMID:
2193107
4.
5.

Gender differences in neurotoxicity of the nigrostriatal dopaminergic system: implications for Parkinson's disease.

Dluzen DE, McDermott JL.

J Gend Specif Med. 2000 Sep-Oct;3(6):36-42. Review.

PMID:
11253381
6.

The nigrostriatal system in Parkinson's disease.

Graybiel AM, Hirsch EC, Agid Y.

Adv Neurol. 1990;53:17-29. Review.

PMID:
1978514
7.

Characteristics of the neuronal firing patterns in the subthalamic nucleus with graded dopaminergic cell loss in the nigrostriatal pathway.

Park SE, Song KI, Suh JK, Youn I.

Conf Proc IEEE Eng Med Biol Soc. 2015;2015:2510-3. doi: 10.1109/EMBC.2015.7318902.

PMID:
26736802
8.

[The neuropsychology of nigrostriatal dopaminergic transmission in Parkinson's disease].

Wallesch C.

Fortschr Neurol Psychiatr. 2011 Dec;79(12):692-5. doi: 10.1055/s-0031-1281596. Epub 2011 Oct 18. Review. German.

PMID:
22009273
9.

PINK1 heterozygous mutations induce subtle alterations in dopamine-dependent synaptic plasticity.

Madeo G, Schirinzi T, Martella G, Latagliata EC, Puglisi F, Shen J, Valente EM, Federici M, Mercuri NB, Puglisi-Allegra S, Bonsi P, Pisani A.

Mov Disord. 2014 Jan;29(1):41-53. doi: 10.1002/mds.25724. Epub 2013 Oct 25.

10.

Correlation between levels of pigment epithelium-derived factor and vascular endothelial growth factor in the striatum of patients with Parkinson's disease.

Yasuda T, Fukuda-Tani M, Nihira T, Wada K, Hattori N, Mizuno Y, Mochizuki H.

Exp Neurol. 2007 Aug;206(2):308-17. Epub 2007 May 23.

PMID:
17604022
11.

Pathogenesis and animal studies of Parkinson's disease.

Oertel WH, Kupsch A.

Curr Opin Neurol Neurosurg. 1993 Jun;6(3):323-32. Review.

PMID:
8507901
12.

Expression of PINK1 mRNA in human and rodent brain and in Parkinson's disease.

Blackinton JG, Anvret A, Beilina A, Olson L, Cookson MR, Galter D.

Brain Res. 2007 Dec 12;1184:10-6. Epub 2007 Sep 29.

PMID:
17950257
13.

Damage to the nigrostriatal system in the MPTP-treated SAMP8 mouse.

Liu J, Wang YY, Liu L, Wang QD, Yuan ZY, Zhang ZX, Gu P, Wang MW.

Neurosci Lett. 2008 Dec 26;448(2):184-8. doi: 10.1016/j.neulet.2008.10.070. Epub 2008 Oct 25.

PMID:
18977411
14.

Loss of PINK1 causes mitochondrial functional defects and increased sensitivity to oxidative stress.

Gautier CA, Kitada T, Shen J.

Proc Natl Acad Sci U S A. 2008 Aug 12;105(32):11364-9. doi: 10.1073/pnas.0802076105. Epub 2008 Aug 7.

15.

Future strategies for the treatment of Parkinson's disease.

Fahn S.

Adv Neurol. 1993;60:636-40. Review. No abstract available.

PMID:
8420202
16.

[Neurobiologic and pharmacologic studies on the pathogenesis of Parkinson disease].

Brücke T, Riederer P.

Wien Med Wochenschr. 1986 Aug 31;136(15-16):401-8. German.

PMID:
2878540
17.

"Ottorino Rossi" Award 2000. New targets for therapy in Parkinson's disease: pathogenesis and pathophysiology.

Greenamyre JT.

Funct Neurol. 2000 Apr-Jun;15(2):67-80. No abstract available.

PMID:
10916718
18.

Physiology and pharmacology of dopamine D2-receptors: their implications in dopamine-substitute therapy for Parkinson's disease.

Mercuri NB, Calabresi P, Bernardi G.

Neurology. 1989 Aug;39(8):1106-8. No abstract available.

PMID:
2569697
19.

Basic research on dopamine in Parkinson's disease and the discovery of the nigrostriatal dopamine pathway: the view of an eyewitness.

Hornykiewicz O.

Neurodegener Dis. 2008;5(3-4):114-7. doi: 10.1159/000113678. Epub 2008 Mar 6.

PMID:
18322366
20.

Mitochondrial energy crisis in Parkinson's disease.

Mizuno Y, Ikebe S, Hattori N, Kondo T, Tanaka M, Ozawa T.

Adv Neurol. 1993;60:282-7. Review. No abstract available.

PMID:
8420144

Supplemental Content

Support Center